Electrameccanica Vehicles Corp. SOLO 深 沪
等待开盘 11-13 09:30:00 美东时间
0.2122
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.2122
- 总市值 2.53万
- 52周最高 1.04
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.1999
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 13.60
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.1999
- 每 手 1
- 风险率 0.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
Azora Therapeutics, a biopharmaceutical company, began trading on Nasdaq as "AZR" and appointed a new executive team and Board of Directors. The company is advancing its AT177 program, targeting an IND submission and Phase 1a trial in the first half of 2027. AT177 is an oral, colon-targeted AhR agonist for ulcerative colitis. The company reported a net loss of $64.6 million for Q3 2026 and had $22 million in cash as of September 30, 2026.
11-12 21:05
Solomon Systech Supplements Property Acquisition Disclosure
Solomon Systech (International) Ltd. ( ($HK:2878) ) has issued an update. Solom...
11-10 19:11
高盛CEO：市场震荡无碍AI融资需求 当前市况仍利于Anthropic上市
高盛首席执行官David Solomon周一接受采访时表示，市场对AI大规模基础设施建设及相关技术的融资与投资需求仍然非常强劲，并预期这一趋势将会持续。
11-10 15:54
Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
Azora Therapeutics, a biopharma company, has formed a five-member board of directors with extensive drug development and governance expertise. The board includes Matt Davidson, CEO and co-founder; Wendy Young, a seasoned medicinal chemist; Aida Habtezion, a gastroenterology and immunology expert; Thomas Soloway, CEO of T-knife Therapeutics; and Paul Hastings, CEO of Nkarta. The company is advancing AT177, an oral aryl hydrocarbon receptor agonist...
11-05 12:00
Figma毛利承压，Arm营收创新高，华尔街承认 AI 回报难测
Figma营收增 43%但毛利率下滑；Arm第二财季营收破 14 亿；高盛等高管坦言AI长期回报不确定性；美科技股因政治预期大涨；道指涨 1,569 点；Waymo宣布终止与Uber独家合作。
11-05 19:50
UBS downgrades Centuria Industrial REIT (CIP) to a Hold
UBS analyst Solomon Zhang downgraded Centuria Industrial REIT to a Hold today a...
11-05 07:56
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Aprea Therapeutics reported Q3 2026 financial results with $37.8 million in cash and provided updates on its WEE1 inhibitor APR-1051, which is advancing in a Phase 1 clinical trial expanded to nine sites. The company plans to present interim Phase 1 data at the EORTC-NCI-AACR Symposium in November 2026 and expects to select the dose for Part 2 in early 2027. APR-1051 is being evaluated in biomarker-defined cancers, with a focus on endometrial can...
11-04 13:30
OSI Systems (OSIS) 2027财年第一季度业绩电话会议：积压订单创历史新高，上调每股收益指引
OSI Systems 2027财年第一季度营收增长5%至4.03亿美元，在手订单达到21亿美元，调整后每股收益（EPS）指引上调至11.28美元至11.64美元。
10-29 21:44
西氏医药服务 (WST) 2026年第三季度业绩电话会议：HVP增长推动业绩指引上调
随着高价值产品（HVP）需求走强，西氏医药服务（West Pharmaceutical Services）2026财年第三季度营收有机增长11.9%，促使其上调全年营收及每股收益（EPS）指引。
10-29 20:14
Solomon Systech Renews Connected Distribution Deal with CEACI
The latest announcement is out from Solomon Systech (International) Ltd. ( ($HK...
10-28 20:18
